Anti‐CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes
Hu C, Deng S, Wong FS, Wen L. Anti‐CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes. Annals Of The New York Academy Of Sciences 2008, 1150: 217-219. PMID: 19120299, DOI: 10.1196/annals.1447.032.Peer-Reviewed Original ResearchConceptsImmunosuppressive drug treatmentType 1 diabetesIslet transplantationDrug treatmentLong-term immunosuppressive drug treatmentSyngeneic islet graft survivalB cell depletion therapyT cell-mediated destructionAccepted therapeutic optionB-cell depletionPancreatic islet beta cellsCell-mediated destructionIslet graft survivalSyngeneic islet transplantationPancreatic islet transplantationIslet beta cellsRecurrent AutoimmuneTolerance establishmentGraft survivalNOD miceTherapeutic optionsAutoimmune diseasesCell depletionInsulin treatmentBeta cells